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ABSTRACT
Background Pathogenic variants of GNB5 encoding 
the β5 subunit of the guanine nucleotide- binding 
protein cause IDDCA syndrome, an autosomal recessive 
neurodevelopmental disorder associated with cognitive 
disability and cardiac arrhythmia, particularly severe 
bradycardia.
Methods We used echocardiography and telemetric 
ECG recordings to investigate consequences of Gnb5 
loss in mouse.
Results We delineated a key role of Gnb5 in heart 
sinus conduction and showed that Gnb5- inhibitory 
signalling is essential for parasympathetic control of 
heart rate (HR) and maintenance of the sympathovagal 
balance. Gnb5−/− mice were smaller and had a smaller 
heart than Gnb5+/+ and Gnb5+/−, but exhibited better 
cardiac function. Lower autonomic nervous system 
modulation through diminished parasympathetic control 
and greater sympathetic regulation resulted in a higher 
baseline HR in Gnb5−/− mice. In contrast, Gnb5−/− mice 
exhibited profound bradycardia on treatment with 
carbachol, while sympathetic modulation of the cardiac 
stimulation was not altered. Concordantly, transcriptome 
study pinpointed altered expression of genes involved 
in cardiac muscle contractility in atria and ventricles of 
knocked- out mice. Homozygous Gnb5 loss resulted in 
significantly higher frequencies of sinus arrhythmias. 
Moreover, we described 13 affected individuals, 
increasing the IDDCA cohort to 44 patients.
Conclusions Our data demonstrate that loss of 
negative regulation of the inhibitory G- protein signalling 
causes HR perturbations in Gnb5−/− mice, an effect 
mainly driven by impaired parasympathetic activity. 
We anticipate that unravelling the mechanism of Gnb5 
signalling in the autonomic control of the heart will pave 
the way for future drug screening.
INTRODUCTION
Intellectual developmental disorder with cardiac 
arrhythmia (IDDCA, OMIM (Online Mendelian 
Inheritance in Man): #617173) is an autosomal 
recessive neurodevelopmental disorder with onset 
in early childhood. Inactivating and hypomorphic 
mutations in the β5 subunit of guanine nucleotide- 
binding protein (GNB5), respectively, cause severe 
and mild forms of the disorder.1 The former is 
associated with cognitive disability, poor or absent 
speech and/or severe cardiac arrhythmias. The 
moderate manifestation of the syndrome, also 
named language delay and ADHD/cognitive impair-
ment with or without cardiac arrhythmia (LADCI) 
syndrome (OMIM: #617182), consists of mild 
intellectual impairment, language delay, attention 
deficit hyperactivity disorder (ADHD) and, in about 
half the cases, severe cardiac arrhythmia.1 2 Some 
patients with IDDCA also showed retinal dysfunc-
tion and nystagmus, epilepsy, hypotonia and gastro-
intestinal problems.1–10 The GNB5 retinopathy 
is a unique combination of dual retinal signalling 
defects reminiscent of features of both bradyopsia 
and rod ON- bipolar dysfunction,5 while the IDDCA 
epilepsy is characterised by early seizure onset (~3 
months of age) with focal seizures rapidly evolving 
into epileptic spasms and consequent generalised 
multifocal discharges.4
The heart rate (HR) is established by the sinoatrial 
node, the pacemaker of the cardiac muscle, and 
controlled by the autonomic nervous system. This 
autonomic nervous system consists of two anatomi-
cally and functionally distinct divisions: the sympa-
thetic and the parasympathetic branches, whose 
functions are often antagonistic but work together 
to maintain balance. In the heart, the postganglionic 
fibres of the sympathetic trunk stimulate the β-ad-
renoreceptors, thereby increasing HR and force of 
contraction. The parasympathetic modulation of the 
heart is primarily mediated by acetylcholine release, 
which activates the M2- muscarinic receptors (M2R) 
present on cells innervated by parasympathetic 
postganglionic neurons, including sinoatrial node 
cells. The activation of M2R triggers Gi/o subfamily 
G- proteins, which turn on G- protein- gated 
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inwardly rectifying K+ channels (GIRK) resulting in membrane 
hyperpolarisation and decrease in HR. Regulator of G- pro-
tein signalling (RGS) proteins negatively regulate the timing of 
this M2R- GIRK signalling. GNB5, a divergent member of the 
Gβ family, has the unique property of forming complexes with 
R7- RGS proteins.11–16 In particular, the GNB5- RGS6 complex is 
involved in cardiac GIRK deactivation kinetics. Rgs6- null mice 
manifested heart conduction anomalies and hypersensitivity to 
parasympathomimetics.17 Zebrafish model defective for gnb5 
gene correspondingly showed reduced heartbeat on reinforced 
parasympathetic stimulation, eye movement defects and altered 
swimming behaviour1 and cardiomyocytes differentiated from 
human induced pluripotent stem cells (iPSCs) edited to engineer 
the GNB5- Ser81Leu missense variant associated with LADCI 
showed a decrease in spontaneous activity on stimulation with 
carbachol compared with normal cells.7
Whereas homozygous Gnb5- null mice recapitulated many of 
the corresponding human disease phenotypes such as learning 
deficiencies, hyperactivity, impaired motor coordination and 
perturbed vision,18–22 a systematic cardiac evaluation has never 
been performed in a mammalian model. Here, we assessed 
heart electrophysiology of Gnb5 mice models. We detected an 
increased frequency of sinus arrhythmias in Gnb5−/− animals, 
which have a smaller heart than wild- type and Gnb5+/−, but 
exhibited better cardiac function. Gnb5−/− mice also displayed 
enhanced parasympathetic sensitivity on stimulation with a 
cholinergic agonist. Consistent with this, transcriptome profiling 
of atria and ventricles revealed overexpression of genes involved 
in cardiac muscle contractility, along with reduced ventricular 
expression of genes required for development of pacemaker cells 
in Gnb5−/− mice. Finally, we expanded the number of ascer-
tained IDDCA individuals and the GNB5 mutational spectrum.
MATERIALS AND METHODS
Enrolment
All affected individuals and their family members were recruited 
in Pakistan (families R–V), France (family W), Egypt (families 
X and Y) and Iran (family Z) after signing a written informed 
consent according to ethical review boards policies. Clinical 
ascertainment included physical examinations, medical history 
interviews and specialised consultations by a certified neurolo-
gist and cardiologist as appropriate. Venous blood was collected 
in EDTA for DNA extraction according to standard procedures.
Exome sequencing
Whole- exome sequencing of families R–V and Z was performed 
by Macrogen, Korea, as described in reference.23 Briefly, target 
enrichment was performed with 2 µg genomic DNA using the 
SureSelectXT Human All Exon Kit version 6 (Agilent Tech-
nologies, Santa Clara, California, USA) to generate barcoded 
whole- exome sequencing libraries. Libraries were sequenced 
on the HiSeqX platform (Illumina, San Diego, California, USA) 
with 50× coverage. Quality assessment of the sequence reads 
was performed by generating QC statistics with FastQC.24 The 
filtering strategy included screening for only exonic and donor/
acceptor splicing variants. In accordance with the pedigree and 
phenotype, priority was given to variants rare or absent in public 
databases (1000 Genomes project, National Heart, Lung, and 
Blood Institute Exome Variant Server, Complete Genomics 69 
and Exome Aggregation Consortium V.0.2).
Trio exome sequencing was performed in proband 37 (family 
W) and her parents using SeqCap EZ Medexome library prepa-
ration kit following manufacturer’s recommendations (Roche, 
Indiana, Indianapolis, USA). Libraries were sequenced on a 
NextSeq500 (Illumina) at a mean depth coverage of 73× with 
93.3% of the target bases above 30×. Genomic alignment 
against the hg19/GRCh37 assembly and variant calling were, 
respectively, done with BWAMEM V.0.7.12 and GATK Haplo-
typeCaller V.3.4 (Broad Institute, Boston, Massachusetts, USA). 
Only highly confident variants were kept for analysis (total 
depth >9, alternative allele depth >4, no strand bias, mosaicism 
>10%). Rare variants were considered as having a frequency 
of <1% in GnomAD v2 dataset. Whole- exome sequencing of 
families X and Y was performed as described in Makrythanasis et 
al.25 Sanger sequencing in each family confirmed the segregation 
of GNB5 variants with the phenotype.
Mouse husbandry
The Gnb5 mouse line was recovered from cryopreserved sperm 
using in vitro fertilisation. The knockout allele was engineered in 
a C57BL/6J inbred genetic background by heterozygous deletion 
of exon 3 in the germline, as previously described.18 22 Genet-
ically modified animals were born and housed in the Animal 
Facility of the Centre for Integrative Genomics, under controlled 
temperature conditions and a 12- hour light–dark cycle with 
free access to water, normal chow and nest building material. 
Mouse genomic DNA was extracted from ear biopsies using the 
hot shot protocol26 and used for genotyping as described.22 To 
prevent the previously documented high mortality of Gnb5−/− 
pups at weaning,18 heterozygous breeding couples used to 
obtain knockout pups were given breeding food pellet enriched 
for proteins and vitamins (Kliba 3336, extrudate). Additionally, 
litters including Gnb5−/− pups were fed from 14 to 28 days of 
age, that is, starting 1 week before weaning, with powdered wet 
maintenance food (Kliba 3436) in a Petri dish placed directly 
onto the floor of the cages, an expedient that should provide 
easier access to the food for the pups.
In vivo transthoracic ultrasound imaging protocol
Transthoracic echocardiography was performed using a 30 MHz 
probe and the Vevo 2100 Ultrasound machine (VisualSonics, 
Toronto, Ontario, Canada). A light anaesthesia was achieved 
with 1%–1.5% isoflurane, maintaining HR at 400–500 beats/
min. The mice were placed in decubitus dorsal on a heated 37°C 
platform to maintain body temperature. The heart was imaged 
in the 2D mode in the parasternal long- axis view. From this view, 
an M- mode cursor was positioned perpendicular to the inter-
ventricular septum and the posterior wall of the left ventricle, 
at the level of the papillary muscles. Diastolic and systolic inter-
ventricular septa, left ventricular posterior wall thickness and 
left ventricular internal end- diastolic and end- systolic chamber 
dimensions were measured. Three separate M- mode images 
were measured and averaged. Left ventricular fractional short-
ening and ejection fraction were also calculated. Fractional short-
ening and ejection fraction were assessed from M- mode based 
on the percentage changes of left ventricular end- diastolic and 
end- systolic diameters and volumes, respectively. We used male 
mice at 9 weeks of age of three different genotypes (Gnb5+/+, 
Gnb5+/− and Gnb5−/−).
In vivo electrocardiography measurements
For in vivo electrocardiography monitoring we have subcutane-
ously implanted biopotential telemetric transponders (ETA- F10, 
Data Sciences International) allowing continuous monitoring in 
conscious freely moving animals at 12 weeks of age. The nega-
tive electrode was implanted at the top of the right pectoral 
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muscle, and the positive one was anchored at the level of the 
last left rib (at about 1 cm of the xiphoid appendix), thus leading 
to a normal lead II trace. Baseline ECG was recorded 10 days 
after device implantation, over a period of 86 hours. After 
30 min of basal measurements, we injected mice with 0.9% 
saline solution (intraperitoneal NaCl, 10 mL/kg) as a vehicle 
control; next, the following compounds were administered 
one at a time: atropine (PubChem CID: 174174, intraperito-
neal, 1 mg/kg), carbachol (PubChem CID: 5831, intraperitoneal 
0.1 mg/kg) and in a subset of mice isoprenaline (PubChem CID: 
3779, intraperitoneal 4 mg/kg) and atenolol (PubChem CID: 
2249, intraperitoneal 2 mg/kg) as well, with a one night interval 
between each injection. The amounts of isoprenaline and aten-
olol were chosen after testing 10 doses ranging from 4 µg/kg 
to 4 mg/kg and 2 µg/kg to 2 mg/kg, respectively. While atropine 
and carbachol respectively inhibit and activate the parasympa-
thetic system atenolol and isoprenaline respectively block and 
promote the sympathetic response.
At the end of the experiment, mice were sacrificed by CO2 
inhalation; the heart was digitally imaged both within its thoracic 
position and after excision. Heart weight was recorded and tibia 
length was measured to normalise the heart weight to body size. 
Images were taken by a Leica DCF295 digital colour camera 
with 3M pixels mounted on a MZ6 stereomiscroscope (Leica, 
Switzerland). The length of the tibia was measured using a preci-
sion calliper after removal from the left leg (without patella nor 
articular cartilage).
Baseline ECG traces were analysed as follows: 10 min of 
recording were analysed using ECG- Auto software in shape 
recognition mode (EMKA Technology, France) every 30 min, 
during night and day phases. Mean values were reported for 
each analysed parameter. During pharmacological challenges, 
ECG recording was analysed continuously, with 10 min steps; 
thus, one mean of each parameter was calculated every 10 min. 
On ECG traces we analysed: (1) RR interval (measured at R 
peak, expressed in millisecond; (2) HR: heart beating rate, calcu-
lated as 60/(RR/1000), expressed in beats/min; (3) PR interval 
(interval between beginning of P wave and R peak, expressed 
in millisecond); (4) QT duration: duration of the QT complex; 
(5) QTc (corrected QT, calculated from QT/√(RR/100)27 (all 
expressed in millisecond) that allows correction of QT from HR 
variations).
Temperature and activity were also recorded. Activity was 
estimated by displacement of the telemetric device from the 
antennas of the recording plate. This measurement was only used 
as a qualitative index of mouse activity/movement. Temperature 
and activity values are mean values of 1- hour interval.
Time-domain heart rate variation (HRV) analysis
Twelve- hour segments of day/night phases were selected from 
the baseline recording period and analysed separately for the 
HRV analysis. Specifically, R wave detection was performed 
and R- R interval time series were obtained. To ensure inclu-
sion of sinus beats only, values not included between R–R 
intervals±2 SD were excluded as reported in Thireau et al.28 
The analysed time- domain HRV parameters, computed using 
Kubios HRV Standard software V. 3.2.0, were: (1) mean R–R 
intervals (NN, in millisecond); (2) SD of all normal R–R inter-
vals (SDNN, in millisecond); (3) square root of the mean 
square differences (RMSSD) between successive normal inter-
vals (in millisecond); and (4) percentage of normal consecutive 
R–R intervals differing by >xms (pNNx, in %, in this study 
x=6 ms).
Arrhythmia assessment
Arrhythmias were identified based on ECG trace (RR interval) and 
counted. Observed arrhythmias were defined as follows: (1) escape 
atrial beat, with a P wave morphology different from that of the sinus 
P wave, classified as ‘long’ and ‘short’ according to the location of the 
P wave on the ECG trace (specifically, long was an escape beat whose 
duration was longer than two normal PP intervals, and short were 
those escape beats that lasted less than two normal PP intervals); (2) 
atrioventricular block defined on ECG by more than one P wave for 
one QRS complex; (3) premature beats; and (4) episodes of tachy-
cardia followed by bradycardia, with HR oscillation between high 
and low values within a few seconds, independently of other type 
of arrhythmias.
Statistical tests
Each parameter measured was reported as mean±SD. Standard 
t- test was used to assess differences between two groups. Anal-
ysis of variance tests, followed by Tukey post hoc tests, were also 
calculated and are displayed. A p value of <0.05 was considered 
significant, and stars on the plots represent the level of signif-
icance (*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001; 
p>0.05 was considered not significant).
Transcriptome profiling, data processing and differential 
expression analysis
A total of 72 RNA sequencing libraries were generated from two 
heart tissues, atria and ventricles, and three brain regions, cerebellum, 
hippocampus and cerebral cortex. Both the entire ventricles (left and 
right) or atria (left and right) were used for the sample processing; 
therefore, the atrial tissue represents a mixture of heart muscle cells, 
as well as sinoatrial and atrioventricular cells. The whole cerebellum, 
the hippocampi from each hemisphere of the brain and the whole 
cerebral cortex were dissected for RNA extraction. For this experi-
ment, we created a cohort of adult (18 weeks) male mice including 
6 Gnb5−/−, 6 Gnb5+/− and 6 Gnb5+/+ animals. Brain transcriptome 
was only assessed in Gnb5−/− and Gnb5+/+ animals. Tissue collec-
tion and processing procedures were designed to minimise biolog-
ical and technical variation. Specifically, tissues were dissociated in 
QIAzol Lysis Reagent (Qiagen) using the gentleMACS Dissociator 
(Miltenyi Biotec). Cell suspension was used to obtain total RNA. 
Genomic DNA contamination was removed by digestion with 
RNase- free Deoxyribonuclease I (Qiagen). RNA concentration and 
purity were measured by ND-1000 spectrophotometer (Thermo 
Scientific, Wilmington, North Carolina, USA), and RNA integrity 
was verified by fragment analyser automated CE system (Advanced 
Analytical Technologies) according to manufacturer’s instructions. 
Libraries were then prepared with TruSeq Stranded RNA Library 
Prep Kit (Illumina) and sequenced on multiple lanes of an Illumina 
HiSeq4000 platform, generating an average of 50M single- end 
125- cycle reads for each sample. Quality of sequence was assessed 
by FastQC V.0.11.4.24 Purity- filtered reads were adapters- trimmed 
and quality- trimmed with Cutadapt V.1.8.29 Reads matching to 
ribosomal RNA sequences were removed with fastq_screen V.0.11.1. 
Remaining reads were further filtered for low complexity with 
reaper V.15–065.30 Reads were then aligned against Mus Musculus.
GRCm38.92 genome using STAR V.2.5.3a.31 The number of read 
counts per gene locus was summarised with htseq- count V.0.9.132 
using Mus Musculus.GRCm38.92 gene annotations. Quality of the 
RNA- seq data alignment was assessed using RSeQC V. 2.3.7.33 Reads 
were also aligned to the Mus Musculus.GRCm38.92 transcriptome 
using STAR V. 2.5.3a,31 and the estimation of the isoforms abun-
dance was computed using RSEM V.1.2.31.34 To assess differential 
expression between genotypes within each tissue, we compared 
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Gnb5−/− and Gnb5+/−± to wild- type specimens. Data analysis was 
performed with the R Bioconductor package DESeq2 V.1.14.1.35 
Differentially expressed genes (DEGs) were identified at the 
Benjamini- Hochberg adjusted p<0.05 level, using Wald test under 
design ~genotype. For gene set enrichment analysis, no direction 
criterion on fold change was applied. Enriched Gene Ontology (GO) 
categories were identified using the enrichment analysis package in 
R/Bioconductor, clusterProfiler,36 considering only categories with at 
least 10 and maximum 500 annotated genes. Nominally significant 
enriched terms were retained for results interpretation.
Western blotting analysis
Tissue lysates, including atria, ventricles, cerebral cortex, cerebellum 
and hippocampi, were prepared in RIPA buffer (Millipore) supple-
mented with protease inhibitors (Thermo Fisher Scientific). Tissues 
were homogenised using the gentleMACS Dissociator (Miltenyi 
Biotec). After SDS- polyacrylamide gel electrophoresis (SDS- PAGE) 
and transfer to nitrocellulose membrane, blots were incubated 
with anti- Gnb5, anti- Rgs7 (both a generous gift from Dr William 
F Simonds) and anti- Gnb3 (Cell Signalling Technology) antibodies, 
separately, and with an antiactin antibody (Sigma), used for loading 
control. Horseradish peroxidase- conjugated anti- rabbit antibody 
(Santa Cruz) and the ECL chemiluminescence system (Millipore) 
were used for detection.
RESULTS
Clinical and molecular features of thirteen novel patients 
with IDDCA
We identified 13 additional IDDCA cases (online supplemental 
figure S1, table S1 and table 1) through exome sequencing of 
nine consanguineous families and data aggregation of multiple 
laboratories and clinical centres via GeneMatcher37 38 or direct 
contacts. Consistent with previous reports,1–10 the carrier of a 
homozygous GNB5 missense variant on Ser81 presented with 
LADCI, the mild form of IDDCA (family W), while the nine 
individuals with biallelic loss- of- function (LoF) alleles due to 
truncating or splicing mutations displayed phenotypes corre-
sponding to the severe end of the disease spectrum (families R 
and S, U and V, and X and Z). The remaining three individuals 
(families T and Y) carrying novel homozygous missense variants 
on Gly215 (family T) and on Leu59 (family Y) similarly presented 
with the severe IDDCA phenotypical spectrum. Clinical features 
of affected individuals are summarised in table 1 and detailed in 
the online supplemental note and table S1. The three missense 
variants (c.644G>A, p.(Gly215Glu), family T, c. 242C>G, 
p.(Ser81Trp), family W and c.176T>C, p.(Leu59Pro), family Y; 
transcript NM_006578.3) were not reported before (figure 1). 
They are predicted by a majority of prediction tools to be likely 
damaging to protein function (online supplemental table S2) and 
are absent from GnomAD V.3.39 To assess possible impact, we 
modelled these three substitutions using the crystal structure of 
the GNB5- RGS9 complex40 and found that each variant could 
impact the potential binding properties of the GNB5 central pore 
(p.(Ser81Trp) and p.(Gly215Glu)) or the protein folding (p.(Le-
u59Pro)) (figure 1A). Specifically, Serine 81 is buried inside a β 
strand of the first WD40 repeat close to the central pore of the 
β propeller structure1 2 where a glycerol molecule is observed 
in pbi structure 2pbi (figure 1A, top left panel). Reminiscent of 
the Ser81Leu variant previously documented,1 a tryptophan at 
position 81 cannot be accommodated without disrupting the 
structure and potential binding properties of the pore. Our 
model suggests that the rearrangements necessary to settle such 
a bulky sidechain will change the channel characteristics. We 
have investigated the related rotamers, emphasising the steric 









Gender 23F, 21M 15F, 19M 7F, 2M 1F
Clinical examination
  Dysmorphic features 11/44 (25%) 10/34 – 1/1
  Congenital malformations 4/44 (9%) 4/34 (heart) – –
Neurological manifestations
  Intellectual disability 37/44 (84%) 32/34 4/9 1/1
  Speech delay 34/44 (77%) 27/34 6/9 1/1
  Hypotonia 33/44 (75%) 29/34 3/9 1/1
  Seizures 25/44 (57%) 25/34 – –
  Behavioural disorders 6/44 (14%) 3/34 (ASD) 3/9 (ADHD) –
  MRI anomalies 8/44 (18%) 8/34 – –
  Sleep disturbance 2/44 (5%) 2/34 – –
Cardiac manifestations
  Sinus sick syndrome 27/44 (61%) 22/34 4/9 1/1
  Pacemaker implantation 6/44 (14%) 4/34 1/9 1/1
Ophthalmological findings
  Nystagmus 26/44 (59%) 26/34 – –
  Strabismus 6/44 (14%) 5/34 – 1/1
  Retinal disease 14/44 (32%) 14/34 – –
Gastrointestinal problems
  Pathological gastric reflux 18/44 (41%) 18/34 – –
Pedigree charts and variants of single individuals are detailed in the corresponding published reports1–4 6 8–10 81 and in online supplemental figure S1. Detailed phenotypical 
information of each affected individuals is reported in online supplemental table S1 and supplemental note.
ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; F, female; IDDCA, Intellectual developmental disorder with cardiac arrhythmia; LADCI, language 
delay and ADHD/cognitive impairment; M, male. by copyright.
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Figure 1 Variants modelling and IDDCA mutational spectrum. (A, top left) Top view of the Gnb5 (orange, PDB entry 2pbi) 3D protein model, showing the 
mutated Trp81 (yellow) and the glycerol molecule (green) in the centre of the pore. The rearrangements necessary to accommodate a tryptophan residue 
at position 81 will change the channel characteristics. The rotamer displayed here highlights clashes of Trp81 with Cys68 (white) and Cys111 (magenta). 
In additional rotamers, the bulky tryptophan sidechain will severely bump into Leu67 (grey), Val87 (pink), Val108 (cyan) and Ala110 (brown). (A, top right) 
As shown in this view of the beta propeller from above, the ‘wild- type’ Gly215 (not shown) lays in a beta- sheet, with on top Ala221 (pink), at the bottom 
Cys200 (magenta), and in front a beta- strand harbouring Val242 (grey) and Val245 (cyan). The presence of Glu215 cannot be tolerated, as it will encroach 
into one of the residues previously enumerated. Another rotamer shows clashes into Val245 (cyan). Overall, all rotamers may also force the sidechain of 
Cys200 (magenta) to reorient itself toward the internal part of the channel to provide space to accommodate glutamine at position 215 (yellow). In this 
position, the Cys200 sidechain will occupy the space dedicated to the glycerol (green), thus changing the properties of the channel. (A, bottom) The Leu59 
(purple label, left panel) is positioned closely to the Leu349 residue just above (red label) in an antiparallel beta- sheet. This secondary structure will likely 
be broken in presence of a proline at that position (blue label, right panel), which in turn will disrupt the protein folding as the proline sidechain will collide 
into Leu349 (red label). (B) Distribution of the IDDCA published and novel variants along the schematically represented 11 exons of the human GNB5 gene 
(transcript NM_006578.3; Ensembl (release 98, September 2019). The variants of IDDCA affected individuals are represented in red (LoF) and the missense 
LADCI variants in blue. The yellow star marks the variant of Middle Eastern descent, while green stars indicate the amber and ochre variants from the Indian 
subcontinent (dark green) and of Pakistani descent (light green), respectively. IDDCA, intellectual developmental disorder with cardiac arrhythmia; LADCI, 
language delay and ADHD/cognitive impairment; LoF, loss of function.
by copyright.
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hindrance- induced local rearrangements associated with the 
tryptophan replacement, whose perturbations were evaluated 
using the backbone- dependent rotamer library implemented in 
the Swiss- PdbViewer.41 Depending on the rotamer, tryptophan 
81 will severely encroach with leucine 67, cysteine 68, valine 
87, cysteine 111, valine 108 and/or alanine 110 (figure 1A, top 
left panel).
Pedigree charts and variants of single individuals are detailed 
in the corresponding published reports1–4 6 8–10 43 and in (online 
supplemental figure S1). Detailed phenotypic information of 
each affected individuals is reported in (online supplemental 
table S1 and Supplemental Note). Abbreviations are as follows: 
M: male; F: female, ASD: Autism Spectrum Disorder, ADHD: 
Attention Deficit Hyperactivity Disorder.
Glycine 215 (figure 1A, top right panel) lies in a beta- sheet, 
between alanine 221 and cysteine 200. It faces a beta- strand 
harbouring valine 242 and valine 245. There is not enough space 
to accommodate the glutamic acid sidechain as it would encroach 
into one or more sidechains of the above- enumerated residues. 
All rotamers would also probably force the sidechain of cysteine 
200 to reorient itself toward the interior of the channel to accom-
modate the glutamic acid 215 sidechain. This will infringe on the 
glycerol molecule space40 changing the channel characteristics. 
Additionally, the c.644G>A, p.(Gly215Glu) variant that affects 
the second to last nucleotide of exon 6 might alter the activity 
of the donor splice site as well as create cryptic exonic splicing 
enhancers or silencers according to the NNSplice, NetGene2 and 
Splicing Finder prediction tools (online supplemental table S2).
Leucine 59 (figure 1A, bottom left panel) is in close contact 
with leucine 349, and both residues, linked by a hydrogen bond, 
belong to an antiparallel beta- sheet. A proline at position 59 
(figure 1A, bottom right panel) will likely destabilise (break) 
this hydrogen bond, thus representing a structural conundrum. 
Locally, the presence of a proline might disrupt the overall 
protein fold as there will not be enough space to accommodate 
this residue, its cyclic sidechain clashing into Leu349.
To date a total of 18 pathogenic GNB5 variants and one homo-
zygous deletion at 15q21.2 encompassing GNB5 gene have been 
identified in 44 individuals with IDDCA (online supplemental 
ffigure 1S 1B and table S1). Suggestive of a founder effect, the 
eight affected individuals from three families (families E–G) 
carrying the Ser81Leu variant all originate from Arab coun-
tries (Morocco, Algeria and Saudi Arabia). Of note, the Greater 
Middle East Variome Project42 (http:// igm. ucsd. edu/ gme/) did 
not identify this variant within 2497 individuals. Similarly, the 
patients from six families (families D, L, P, R, S and V) harbouring 
the amber nonsense c.906C>G (Tyr302*) variant are from the 
Indian subcontinent (one from India and five from Pakistan). 
Another variant modifying the Tyr302 codon in an ochre codon 
(c.906C>A) was found in two additional Pakistani families 
(families N and U), suggesting again a possible founder effect. 
Of note, the same ochre variant was shown to be de novo on the 
paternal allele of the proband of the Chinese descent family O.9 
The 34 IDDCA individuals present with the severe end of the 
disease spectrum, which is characterised by severe ID (32 out of 
34) with poor or absent speech (27/34), early onset sinus node 
dysfunction (22/34) with 4/22 who had a pacemaker implanted, 
variable visual abnormalities (26/34), seizures (25/34), hypo-
tonia (29/34) and gastrointestinal problems (18/34). Addition-
ally, 9/34 individuals showed different types of dysmorphic 
features (table 1 and online supplemental table 1), and MRI 
evaluation revealed altered brain structure in 8/34 children, with 
four having thinner corpus callosum, two having long posterior 
and hypogenesis of corpus callosum, respectively, one cerebral 
atrophy and one cerebral and cerebellar cortical atrophy. Three 
individuals (individual 16, family H; individual 39, family X; 
and individual 44, Family Z) showed autistic features, and the 
other two displayed sleep disturbances (individual 27, family 
N, and individual 29, family P). All severely affected individuals 
carry either biallelic truncation mutations or biallelic missense 
variants that probably result in LoF. Nine patients displayed the 
milder LADCI syndrome and biallelic missense variants at posi-
tion 81: 4/9 presented with mild ID with 6/9 showing language 
deficits; 4/9 were noted to have sinus node dysfunction (one of 
which with pacemaker implantation); and 3/9 were reported 
with impaired fine motor skills. Behaviorally, 3/9 patients exhib-
ited ADHD. The remaining patient (family J) is compound 
heterozygous for the LoF p.Asp74Glufs52* and the Ser81Leu 
variants.3 She presented with an intermediate manifestation of 
the symptoms with mild ID accompanied by speech delay, hypo-
tonia and sinus bradycardia (table 1). Like patient 21 from family 
I who carries the same LoF p.Asp74Glufs52* combined with a 
different missense, p.(Arg246Gln),8 she is affected by hearing 
loss (online supplemental table S1).
Gnb5 knockout mouse cohort
To model the cardiac manifestations occurring in IDDCA 
syndrome, we used the mouse model knockout for Gnb5 (Gnb5–
/–), thus mimicking a complete LoF. Whereas ~66% of the pups 
carrying the homozygous null allele were previously reported 
to die prior to or at weaning,18 preweaning mortality was very 
low in our husbandry setting (see Materials and methods). We 
experienced only 5%, 11% and 6% of losses in the three cohorts 
we generated by mating heterozygous parents (figure 2A). We 
recorded two to eight breeding events during three generations 
of husbandry with an average litter size of 4–10 pups. The vast 
majority of preweaning lethality appears to be associated with 
Gnb5–/– as shown by the quasi- Mendelian distribution of geno-
types (figure 2A). We longitudinally monitored the body weight 
of Gnb5+/+ (wild type), Gnb5+/– and Gnb5–/– male and female 
mice from 3 to 46 weeks of age (figure 2C,D). We confirmed 
previous reports18 22 that showed that female and male knockout 
animals are smaller (figure 2B–D) and that heterozygote male 
mice are heavier (figure 2). Importantly, knockout mice had 
a smaller heart (figure 2E), even smaller than expected when 
the heart weight was normalised to the tibia length, a proxy 
for animal size (figure 2F). During animal handling, no obvious 
gender differences were observed regarding development, 
behaviour or other gross phenotypes.
Ultrasound scans pinpointed increased cardiac function in 
Gnb5 knockout mice
To characterise the Gnb5 knockout mouse line at cardiac level, we 
first performed ultrasound scans in baseline conditions. We used 
16 Gnb5+/+, 8 Gnb5+/– and 16 Gnb5–/– male mice (9 wo (weeks 
of age)) and analysed heart morphology and function (see Mate-
rials and methods section). Echocardiography confirmed that 
Gnb5–/– animals had smaller hearts, as demonstrated by reduced 
ventricular chambers both in diastole and systole (figure 3A). 
Consequently, ventricular volume was also smaller (figure 3B). 
Estimated left ventricular weight was significantly lower in 
Gnb5–/– compared with Gnb5+/– and wild- type (figure 3C). Left 
posterior ventricular wall and interventricular septum thickness 
were not substantially modified (online supplemental figure 
S2A, B). Interestingly, Gnb5–/– mice demonstrated improved 
cardiac function, as judged by increased fractional shortening 
(figure 3D) and ejection fraction (figure 3E). However, stroke 
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volume (figure 3F) and cardiac output (figure 3G) were similar 
to those measured in wild- type mice. Notably, and unexpect-
edly, Gnb5+/–have a bigger heart (figure 3A–C) compared with 
wild type, while their cardiac function remains unchanged 
(figure 3D–E). Therefore, the increased stroke volume (figure 3F) 
and cardiac output (figure 3G) reflected an increased volume of 
blood pumped by the ventricle.
Taken together, these results indicated that Gnb5–/– mouse 
hearts were smaller than that of the other two genotypes but 
compensated their smaller size by increased cardiac efficiency.
Loss of functional Gnb5 determines the onset of sinus 
arrhythmias
As cardiac arrhythmia in the form of bradycardia and ectopic 
beats is one of the core symptoms in IDDCA, we examined 
HRVs in Gnb5 mouse models with in vivo ECG monitoring. 
ECG was performed at 12 weeks on the same male mice used for 
echocardiography. Baseline ECG parameters were not different 
among Gnb5+/+, Gnb5+/– and Gnb5–/– animals, except for HR in 
knocked- out animals that showed a trend toward higher values 
(online supplemental figure S2C, minimum and maximum HR 
values registered in wild- type were 313 and 741 beats/min, 
while lowest and greatest HR values in knockout were 349 and 
744 beats/min, significance varying between p=1.28E-04 and 
p=0.9971, over 36 daylight time points).
Close inspection of baseline ECG over a 24- hour window 
allowed the quantification and characterisation of small changes 
in the intervals between successive heartbeats (RR interval) corre-
sponding to cardiac arrhythmias (Materials and methods). The 
24- hour ECGs unearthed a significant increase in arrhythmic 
events in Gnb5–/– mice compared with heterozygous and wild- type 
littermates. We counted on average 53 short atrial escape beats in 
Gnb5+/+ and 204 in Gnb5–/– animals over 24 hours (figure 4B–E, 
p=4.936e-06). Long atrial escape beats (figure 4C–F; 1 vs 117 
events, p=7.792e-06) and atrioventricular blocks (figure 4D–G; 
0.6 vs 30 events, p=0.04078) were similarly observed significantly 
more frequently in knockout animals. Few episodes of tachycardia 
followed by bradycardia and premature beats were also observed 
in homozygous knockouts.
These results demonstrated that Gnb5–/– mice have a defect at 
the level of sinus node as well as cardiac conduction anomalies 
linked to the atrioventricular node. Of note, we did not assess for 
other anomalies.
Gnb5-deficient mice exhibit higher cholinergic sensitivity and 
normal sympathetic activity
Human homozygote carriers of GNB5 pathogenic variants 
show severe bradycardia at rest with a maximal HR unchanged 
during exercise. Zebrafish and human cell modelling supported 
predominantly parasympathetic modulation in the aetiology of 
Figure 2 Gnb5 mouse line features. (A) Mouse mating strategy and gender and genotype distribution over three successive generations. Preweaning and 
postweaning mortality is reported for each colony. (B) Size of Gnb5+/+ and Gnb5−/− mice. (C,D) Body weights profile monitored from 3–46 weeks of age. 
All mice were weaned on week 3. Data are shown as mean±SD. (C,D) Panels separate body weights according to sex. Gnb5+/+ is depicted in grey, Gnb5+/− 
in blue and Gnb5−/− in red. (E) At sacrifice, neither significant morphology difference nor thoracic position of the heart were observed among groups. (F) Bar 
plot showing that Gnb5−/− hearts (red, n=16) are smaller compared with the other genotypes (Gnb5+/−, blue (n=8) and Gnb5+/+, grey (n=16)). Data are 
shown as mean of the ratio between heart weight and tibia length (used to normalise for animal size)±SEM. Asterisks on the plots represent the level of 
significance: *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001; p>0.05 was considered not significant.
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HR disturbances in IDDCA individuals.1 7 To better assess the 
possible involvement of the autonomic innervation, we used an 
in vivo mammalian model system whose physiology is closer to 
humans. We used ECG telemetry to monitor HR and observed 
higher HR in baseline conditions (online supplemental figure 
S2C) possibly reflecting a higher rate of activity of the Gnb5–/– 
mice, as measured qualitatively here and reported previously22 
(online supplemental figure S2D,E), or alternatively differences 
in the HR regulation.
Parasympathetic blockade with atropine (1 mg/kg) had 
a positive chronotropic effect; that is, HR increased (HR 
Gnb5+/+=690 beats/min±68, HR Gnb5+/–=700 beats/min±34, 
HR Gnb5–/–=758 beats/min±28 (p+/+ vs. +/–=0.63, p+/+ vs 
–/–=2.62E-03, p+/– vs –/–=2.38E-03)) (online supplemental figure 
S3A). In contrast, carbachol administration (0.1 mg/kg) triggered 
a rapid decrease of the HR in the three groups, with a significant 
effect in Gnb5–/– mice, whose HR dropped until 335 beats/min 
(HR Gnb5+/+=448 beats/min±147, HR Gnb5+/–=415 beats/
min±157, HR Gnb5–/–=335 beats/min±141 (p+/+ vs –/–=3E-02; 
online supplemental figure S3B). HR quickly recovered in all 
genotypes. The duration of the bradycardia was similar in the 
three groups (~1 hour). Moreover, since the baseline HR of 
knockout animals was higher, when expressed in relation to the 
basal values, the effect of atropine was not different in the three 
groups of mice (p+/+ vs +/–=0.22, p+/+ vs –/–=0.07, p+/– vs –/–=0.77; 
figure 5A), while the carbachol- induced bradycardia was more 
severe in Gnb5–/– (p=1.79E-03, figure 5B).
To mimic the sympathetic response and investigate a possible 
role of the β-adrenergic response in the heart rhythm pertur-
bations of IDDCA syndrome, we challenged Gnb5+/+ and 
Gnb5–/– animals with either isoprenaline or atenolol. Injection 
of the sympathetic agonist isoprenaline (4 mg/kg) resulted in a 
prolonged (~1 hour) increase of HR, with values comparable in 
both genotypes (p=0.41, online supplemental figure S3C). HR 
slowly decreased to baseline; this reduction reached lower than 
baseline values in Gnb5–/– mice (online supplemental figure S3C). 
However, when expressed in percentage of the baseline, the 
tachycardia seemed stronger in wild- type (p=0.09, figure 5C).
The sympathetic antagonist atenolol (2 mg/kg) induced a 
similar decrease of HR in both groups (p=0.73, p=0.22 when 
compared with baseline (online supplemental figure S3D and 
figure 5D).
Figure 3 Morphological and functional parameters measured by ultrasound scan in Gnb5+/+, Gnb5+/− and Gnb5−/− male mice. (A) Left ventricular internal 
diameter at diastole (left) and systole (right). (B) Left ventricular volume in diastole (left) and systole (right). (C) Mass of the left ventricle. (D–G) Cardiac 
function expressed as fractional shortening (D), ejection fraction (E), cardiac output (F) and stroke volume (G). Parameters unchanged between the three 
genotypes are shown in online supplemental figure S2A,B.
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Figure 4 Cardiac arrhythmias recorded in Gnb5 mouse line. (A) Normal ECG trace recorded in wild- type male mice with the main spikes specified as used 
in the text. (B,C) Gnb5−/− male mice ECG traces showing escape atrial beats classified as short (B) and long (C) and characterised by the occurrence of a 
late P- wave (red arrow). (D) Gnb5−/− male mice ECG trace demonstrating atrioventricular blocks, with more than one P- wave per QRS complex (consecutive 
red arrows). (E–G) Respective box plots indicating the number of arrhythmias, that is, the number of short (E) and long (F) escape atrial beats and 
atrioventricular blocks (G) per 24 hours. ns, not significant.
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These results indicate that the Gnb5–/– mice bradycardia results 
from enhanced parasympathetic (cholinergic) stimulation/reflex. 
Our data also suggest an increased sympathetic activation when 
animals are under stress, that is, when they are challenged by the 
injection of drugs.
In contrast to individuals affected with IDDCA, Gnb5–/– mice 
showed a higher HR in baseline conditions (online supplemental 
figure S2C and S3A- D, first three data points). We hypothesised 
that such discrepancy could be linked to different autonomic 
nervous system tone between human and mouse.43 We there-
fore analysed the response to the administration of drugs to 
determine which of the parasympathetic and sympathetic system 
mostly influences baseline HR. Atropine- mediated parasympa-
thetic inhibition induced an increase in HR with a variation from 
the baseline, which was smaller in knockout animals than in wild 
types (figure 5E), pinpointing that the parasympathetic tone is 
lower in Gnb5–/– mice. Conversely, the sympathetic blockade by 
atenolol induced a greater reduction of the HR in Gnb5–/– than 
control littermates (figure 5E) evocative of the greater sympa-
thetic tone observed in basal conditions. Of note, the control 
responses mediated by NaCl injection also showed a difference 
in HR attributable to increased parasympathetic/sympathetic 
balance; the HR increase, due to the stress caused by the injection 
and animal handling, was less pronounced in Gnb5–/– mice. Our 
results suggest that higher basal HR in Gnb5–/– mice could be 
due to lower parasympathetic tone and higher sympathetic tone.
To further assess the functioning of cardiac autonomic 
regulation, we performed time domain analysis of HRV in 
Gnb5+/+ and Gnb5–/– mice. We measured NN, SDNN, RMSSD 
and pNN6 during light (day) and dark (night) phases in each 
genotype. Whereas all parameters differ in the wild- types, the 
knockouts showed no significant HRV differences between 
light and dark phases (table 2) confirming that differences in 
RR intervals (NN), and hence in HR, were greater in Gnb5+/+ 
(pNN=1.25E-08, table 2) than in Gnb5
–/– mice (pNN=0.72, 
table 2). This suggests abnormal autonomic regulation, in 
particular via the parasympathetic system in the Gnb5–/– mouse. 
Concordantly, RMSSD, which reflects short- term variations in 
HR, and pNN6, both measures of the parasympathetic nervous 
system regulation, were significantly different between night 
and day in Gnb5+/+ mice (pRMSSD=4.38E-05, ppNN6=9.71E-06; 
table 2), while they were almost unchanged in Gnb5–/– mice 
(pRMSSD=0.65, ppNN6=0.9, table 2). Similarly, SDNN that indi-
cates the total autonomic variability, fluctuated in Gnb5+/+ mice 
(pSDNN=1.16E-02, table 2) but not in Gnb5
–/– mice (pSDNN=0.61, 
table 2) at night.
Figure 5 Pharmacological administration of compounds mimicking parasympathetic and sympathetic stimulation. (A) HR monitoring after injection of 
atropin (intraperitoneal 1 mg/kg). (B) Bradycardia measured in response to carbachol (intraperitoneal 0.1 m/kg). (C) HR variation in response to atenolol 
(intraperitoneal 2 mg/kg). (D) Increased HR after isoprenaline administration (intraperitoneal 4 mg/kg). Data points are expressed as percentage of the 
baseline values. (E) Smaller parasympathetic and bigger sympathetic blockade in Gnb5−/− mice (red), compared with wild- type littermates (black), indicative 
of lower parasympathetic and higher sympathetic tones in basal conditions. HR, heart rate.
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All parameters were significantly reduced during the light phase 
when comparing Gnb5+/+ and Gnb5–/– mice (pNN=3.45E-03, 
pSDNN=4.76E-02, pRMSSD=9.07E-03, ppNN6=7.34E-04; table 2).
Taken together, these results demonstrated an impaired auto-
nomic regulation in Gnb5–/– mice, in particular a lower modula-
tion of the parasympathetic activity.
Transcriptome analysis of Gnb5 mice
To explore the transcriptional consequences of Gnb5 loss in the 
heart, we profiled the transcriptomes of atria and ventricles of 
Gnb5–/–, Gnb5+/– and wild- type male mice at 18 weeks of age 
using RNA- sequencing (RNA- seq) (online supplemental table 
S3). RNA- seq libraries were sequenced to a median depth of 
~50 000 000 single- end reads per samples. Samples clustering 
(using Poisson model44) to define the global relationship among 
all samples, showed a very clear separation of atria and ventricles 
(online supplemental figure S4A) as well as of hippocampi, cere-
bellum and cerebral cortex (online supplemental figure S4B). 
Transcripts quantification confirmed that Gnb5, the orthologue 
of GNB5, is expressed in the brain (online supplemental figure 
S5) and cardiac tissues (atria and ventricles; figure 6A,B, top) 
of adult mice and that its expression levels correlated with gene 
dosage. We identified 98 significantly DEGs in atria (online 
supplemental table S4) and 63 in ventricles (online supplemental 
table S5) applying a false discovery rate method for multiple 
testing with a 5% threshold. Consistent with the phenotype 
described in Gnb5–/– mice, we found altered expression of 
genes involved in cardiac muscle contractility, HR regulation 
and cardiac conduction. Among the upregulated genes falling 
into these categories in atria were Npr3 (p=9.71E-04), Comp 
(p=3.7E-05) and Scn10a (p=2.88E-02), while downregulated 
transcripts were Myh7 (p=1.31E-02), Lmod2 (p=1.04E-04) and 
Agt (p=7.97E-03) (figure 6A, top). Profiling of the ventricles 
demonstrated significant upregulation of Lrrc10 (p=3.91E-02), 
Tnnt2 (cardiac troponin, p=2.88E-02), Scn10a (p=1.84E-02) 
and Drd2 (p=8.28E-04) (figure 6B, top), and reduced expression 
Table 2 Results of HRV analysis
Genotype Gnb5+/+ Gnb5−/− Gnb5+/+ vs Gnb5−/−
Night/day Night Day P value Night Day P value P value P value
Mean SD SEM Mean SD SEM
Night 
versus 




Mean RR (NN) 112.27 10.32 2.66 136.81 13.25 3.31 1.25E-08 110.00 7.45 1.92 111.63 24.18 6.04 0.72 0.21 3.45E-03
SDNN 23.47 3.44 0.89 26.56 5.02 1.25 0.012 24.05 4.16 1.11 23.17 3.31 0.83 0.61 0.94 4.76E-02
RMSSD 4.77 1.74 0.45 6.54 2.10 0.53 4.38E-05 5.05 2.49 0.64 4.69 1.05 0.26 0.65 0.86 9.07E-03
pNN6 13.81 8.96 2.31 24.13 10.49 2.62 9.71E-06 13.33 7.98 2.06 13.21 5.00 1.25 0.90 0.88 7.34E-04
HRV parameters measured in time- domain HRV analysis over 12- hour nocturnal and 12- hour diurnal intervals. Values are reported as mean; SD and SEM were calculated and 
reported. Standard t- test was used to assess differences between Gnb5+/+ and Gnb5−/− groups, as well as for differences between day and night. Description of the parameters 
used can be found in the Materials and Methods section.
HRV, heart rate variation; NN, mean R–R interval; RMSSD, square root of the mean square difference; SDNN, SD of all normal R–R intervals.
Figure 6 Comparison of transcriptome profiles of atria and ventricles in Gnb5+/+, Gnb5+/ and Gnb5−/− male mice. (A) Atrial expression profiles of Gnb5 
(top, left) and other DEGs (top Lane); Gnb and Rgs transcripts quantification in atria (bottom lane). (B) Ventricular expression profiles of Gnb5 gene (top, left) 
and other DEGs (top lane); Gnb and Rgs transcripts quantification in ventricles (bottom). DEG, differentially expressed gene.
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of Tbx18 (p=1.32E-04). Notably, the expression level of TNNT2 
gene was not modified in GNB5- Ser81Leu hiPSC.7 Correspond-
ingly, nominally enriched gene sets were associated with devel-
opment of the cardiac conduction system (GO:0003161, online 
supplemental table S6, S7), regulation of HR (GO:0002027, 
online supplemental table S6, S7) and cardiac muscle contraction 
(GO:0060047, GO:0060048; online supplemental table S6, S7). 
MYH7 and TNNT2 encode sarcomeric proteins, essential for 
contraction and relaxation of the heart muscle, and mutations in 
these genes have been linked to cardiomyopathy.45
Scn10a encodes the voltage- gated sodium channel NaV1.8. 
Its human orthologue was associated with HR regulation and 
genome- wide association studies suggested it as a modulator of 
PR interval duration, that is, atrial conduction time.46 Lrrc10 
and Lmod2 are associated with dilated cardiomyopathy in 
both human and mice47–50; while Lrrc10 functions in the sarco-
meric Z- disc and the T- tubule components, involved in muscle 
contraction,47 loss of functional Lmod2 has been linked to short 
thin filaments and reduction in maximum calcium- activated 
force production.48 Rodent ventricular cardiomyocytes are 
converted into spontaneous firing cells (eg, sinoatrial- node pace-
maker cells) by expression of the transcription factor Tbx18,51 
whereas a polymorphism in DRD2 has been associated with 
motor learning and HR.52 RYR1 has a dominant role in muscles 
contractility, even though it is more prominently associated with 
skeletal muscle.53 Common variants in RYR1 are associated with 
left ventricular hypertrophy.54
Given that (1) Gnb5 has four paralogous genes, with ~50% 
sequence identity55 56; (2) the respective encoded proteins may 
have redundant function; (3) the propagation of the Gnb5- 
mediated signal is controlled by RGS15 16 57; and (4) Gnb5 and 
Rgs (ie, Rgs6 and Rgs7) are coexpressed both at RNA (online 
supplemental figure S6A,B) and protein levels,17 we investi-
gated the expression patterns of these two families of genes in 
our transcriptome profiles to investigate possible compensatory 
mechanisms. We found significant upregulation of Gnb3 in 
ventricles (figure 6B, bottom, p=5.21E-03) and a trend toward 
increased expression level in atria (figure 6A, bottom, p=0.24). 
The genes encoding the other Gβ subunits, named Gnb1, Gnb2 
and Gnb4, did not change expression (figure 6A,B, bottom). 
In ventricles, the three R7- Rgs expressed in heart, Rgs6, Rgs7 
and Rgs11, showed a trend towards increased expression 
when Gnb5 was knocked out (figure 6B, bottom). Only Rgs6 
showed a similar trend in atria (figure 6A, bottom). Gnb5+/− 
mice showed no or very subtle changes of their transcriptome 
compared with controls; we detected only six DEGs in atria 
(online supplemental table S8) and one in ventricles (online 
supplemental table S9) beside the engineered Gnb5. Profiling 
Gnb5 protein expression revealed detectable levels in the heart 
of wild- type mice, along with abundant presence in three brain 
regions (cortex, cerebellum and hippocampi), while immuno-
blotting of Gnb5−/− tissues verified the complete absence of the 
protein (online supplemental figure S6C). Notably, we detected 
no compensatory changes in either Gnb3 or Rgs7 levels; the 
two proteins were undetectable in Gnb5−/− atria and ventri-
cles (online supplemental figure S6C). This suggests that Gnb3 
protein stability may be decreased and further demonstrates that 
the physical association with Gnb5 is critical for the stability of 
the Gnb5/R7- Rgs complex, as previously described for Rgs6.17 
Gnb5 and Rgs7 proteins were enriched in atria compared with 
ventricles in wild- type mice (online supplemental figure S6C).
We further investigated transcriptome signatures in three brain 
regions relevant to the IDDCA pathology: the cortex because 
of its role in higher cognitive function, the hippocampus as it 
participates in the formation of long- term and spatial memories 
and the cerebellum for its motor control and language processing. 
Cerebellar and hippocampal anomalies were documented in 
Gnb5 knockout pups.22 Overall, we observed 206 DEGs in cere-
bellum, 105 in hippocampus and 48 in cerebral cortex (at false 
discovery rate (FDR) 5%) (online supplemental table S10- S12). 
These genes resulted in over- representation of gene ontology 
(GO) terms involved in regulation of excitatory postsynaptic 
membrane potential (GO:0060079), regulation of neurotrans-
mitters secretion (GO:0046928), learning (GO:0007612) and 
synapse organisation (GO:0050808), regulation of inositol 
3- phosphate (GO:0014065), regulation of cAMP- mediated 
signalling (GO:0043951) (in cerebellum, online supplemental 
table S13); visual perception (GO:0007601), phototransduc-
tion (GO:007602), guanylate cyclase activity (GO:0031282) 
and regulator of signalling receptors (GO:2000272) (in hippo-
campus, online supplemental table S14); and sensory percep-
tion of light stimuli (GO:0050953) and lens development 
(GO:0002088) (in cortex, online supplemental table S15).
Quantitative RT- PCR and microarray data previously indi-
cated altered expression levels of genes implicated in neuronal 
development and function, such as down- regulation of Grid2 
(glutamate ionotropic receptor, delta 2) and upregulation of 
Synpo (synaptopodin),22 as well as increased expression of 
Guca1a and Guca1b, calcium- binding protein activating photo-
receptor guanylate cyclases. Guca1a (phippocampus=1.81E-03) and 
Guca1b (pcerebellum=1.56E-302, phippocampus=1.9589E-196, pcor-
tex=2.209E-178) were DEGs in the brain of Gnb5 knockout 
mice; they showed significant upregulation (online supplemental 
figure S5). Synpo showed a trend of increased expression in the 
hippocampus (online supplemental figure S5B, p=0.55).
A subset of additional DEGs included Grin2a (p=1.044E-06), 
Snca (p=7.96E-03), Gnai2 (p=7.79E-03) and Kcnj2 (p=0.04), in 
the cerebellum (online supplemental figure S5A), Hes5 (p=0.04) 
and Sox6 (p=0.02) in the hippocampus (online supplemental 
figure S5B) and Ntrk3 (p=9.69E-04) and Cacna2d4 (p=0.03) 
in the cortex (online supplemental figure S5C). The glutamate- 
gated ion channel Grin2a protein plays important roles in 
long- term potentiation and in efficient synaptic transmission. 
Disruption of this gene is associated with focal epilepsy and 
speech disorder with or without cognitive disability.58 Hes5 and 
Sox6 genes, respectively, are a transcriptional repressor and acti-
vator, required for the regulation of transition timing of neuro-
genesis and gliogenesis in mammalian neocortical development59 
and in the normal development of the central nervous system.60 
Cacna2d4 encodes for a calcium channel whose mutations are 
associated with retinal dysfunction in human.61 The expression 
of transcripts encoding for different Gβ subunits and R7- RGS 
genes remained unchanged (online supplemental figure S5 A- C, 
bottom), suggesting that the brain could be less proficient than 
the heart in compensating dysregulated pathways. Rgs7 protein 
level was greatly reduced in Gnb5−/− brain, further emphasising 
the Gnb5/R7- Rgs codependence (online supplemental figure 
S6C).
DISCUSSION
The advent of high- throughput sequencing allowed identifica-
tion of the cause of hundreds of Mendelian diseases,62 in partic-
ular those involving intellectual disability.63 For example, data 
aggregation of exome sequencing uncovered a link between 
variants in genes encoding the Gβ subunits of the heterotrimeric 
G- proteins with a group of neuropsychiatric conditions with 
cardiac manifestations and ophthalmic pathologies.1–4 6 8–10 64–79 
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Mutations in GNB5, encoding the divergent Gβ5 subunit of the 
guanine–nucleotide binding protein family, were recently shown 
to be causative of the autosomal recessive IDDCA syndrome. 
Differently from Gβ1–4, Gβ5 forms irreversible dimer with the 
G- protein γ-like domain80 present in the R7 regulator group of 
G- protein signalling proteins (R7 RGS). Dimerisation with Gβ5 
is absolutely required for the stability of the R7 RGS proteins16.
Genotype–phenotype correlation showed that carriers of 
truncating GNB5 variants present with the severe form of this 
syndrome, while missense alleles are associated with milder 
phenotypical manifestations. Recently, an individual carrying 
a homozygous deletion spanning three genes, BCL2L, GNB5 
and MYO5C, was reported to display a phenotype which over-
laps significantly with the IDDCA manifestations,81 further 
confirming that this phenotype is associated with loss of function 
of GNB5. In this work, we increased the number of reported 
individuals with IDDCA and associated variants, through 
identification of nine additional families and five novel caus-
ative variants. The core symptoms of IDDCA include cogni-
tive disability, epilepsy, retinopathy and cardiac arrhythmia.1–10 
This is a life- long condition with a risk of sudden death. Six 
of the seven deceased IDDCA individuals are suspected to have 
died from a sudden cardiac arrest secondary to an arrhythmia. 
Although the mutational spectrum of this syndrome has already 
been partly defined, the overall molecular mechanism by which 
perturbations of GNB5 translate into IDDCA phenotypical 
manifestations remains unclear. Modelling in zebrafish and 
cardiomyocytes differentiated from human iPSCs provided some 
initial answers1 7; however, we thought that the mouse would 
be a more appropriate tool to investigate consequences of this 
human syndromic neurodevelopmental condition. As little was 
known about possible cardiac conduction anomalies in mice, 
we characterised both the cardiac phenotype and molecular 
outcome of knocking- out Gnb5. Gnb5−/− animals were smaller 
and had smaller ventricles, and therefore the chambers would 
contain less blood as a consequence. However, they exhibited 
an increase in fractional shortening and ejection fraction, a sign 
of compensatory cardiac function. The quantity of blood ejected 
by the ventricles, as defined by the cardiac output and stroke 
volume, remained unchanged between Gnb5−/− and Gnb5+/+ 
mice, indicating that Gnb5−/− heart has adapted to ensure that it 
efficiently meets the body’s demands for perfusion.
ECG measurements showed that, conversely to IDDCA 
affected individuals who present with severe bradycardia at 
rest, Gnb5−/− mice have higher HRs in basal condition, espe-
cially during the day, the mouse sleeping phase. Zebrafish 
knocked- out for all gnb5a and gnb5b copies present in the fish 
genome, showed a similar trend of increased basal HR.1 It is 
plausible that these differences are linked to a lower parasym-
pathetic tone in fish and rodents compared with humans. Of 
note, we showed that the parasympathetic and sympathetic 
tones of Gnb5−/− mice were, respectively, lower and higher than 
those of controls (figure 5E), thus possibly influencing the basal 
HR. Whereas we cannot conclude that this higher basal HR is 
exclusively due to changes in HR regulation as we and others 
observed an increase in activity of Gnb5−/− mice21 22 (online 
supplemental figure S2D), the zebrafish model showed no sign 
of hyperactivity.1 In normal conditions, HR is balanced by the 
synergic interactions between the sympathetic and parasympa-
thetic nervous systems. Our HRV analysis, aimed at assessing 
such sympathovagal balance, confirmed a reduced modulation 
of the parasympathetic stimulation in the heart of Gnb5−/− mice 
(table 2).
ECG recordings additionally revealed a high number of 
arrhythmias in knockout animals, including escape beats, tachy-
cardia/bradycardia episodes and atrioventricular block. These 
sinus arrhythmias and conduction problems, reminiscent of 
arrhythmias observed in IDDCA subjects, further corroborate 
the involvement of Gnb5 gene in altered cardiac function and 
irregular heartbeat. Finally, our mice study showed that Gnb5- 
inhibitory signalling is essential for the parasympathetic control 
of the HR as suggested by previous studies in other models.1 7 
Knockout mice treated with a parasympathomimetic presented 
with bradycardia, while injection of an antiparasympathetic drug 
atropine had the same effect as in wild type. The β-adrenergic 
activity of Gnb5−/− mice was unaltered, suggesting a normal 
sympathetic modulation of the cardiac stimulation, and further 
confirming that the more efficient cardiac function is an adapta-
tion to counteract the reduced size of the Gnb5−/− heart.
Consistent with this observation, transcriptome profiling 
provided insights into modifications of cardiac contraction 
properties, along with reduced ventricular expression of genes 
required for development of pacemaker cells. Instead of specific 
signals (eg, pacemaker function genes in atria), genes related to 
heart muscle contraction (eg, Myh7 and Lmod2 in atria, Tnnt2 
and Lrrc10 in ventricles) and conduction system functions (eg, 
Agt and Npr3 in atria, Tbx18 in ventricles and Snc10a in both) 
were identified as DEGs in both atria and ventricles in Gnb5−/− 
animals. These transcriptome alterations may shed light on the 
mechanisms that result in the pathology of IDDCA. Approaches 
like single- cell RNA- sequencing combined with the isolation of 
sinoatrial node cells are warranted to complement our findings in 
the future. Globally, these data further challenge our study, since 
we cannot unravel whether the transcriptome modifications are 
cause or consequence of the augmented contractility. We argue, 
in line with the aforementioned results, that we are possibly 
investigating a compensatory mechanism. Interestingly, mice 
lacking Gnb5 overexpress Gnb3, a gene encoding a different Gβ 
subunit and involved in the activation of GIRK channels.82 In 
contrast to Gnb1 and Gnb4 that have a well- documented role in 
the nervous system,76 83 Gnb3- null mice presented with cardiac 
manifestations, including slower HRs. However, their isolated 
hearts responded equivalently to muscarinic receptor- adrenergic 
and β-adrenergic receptor- stimulations, thus suggesting that 
Gnb3 is unlikely to be involved directly in the G- protein signal-
ling controlling heart pacemaker activity.84 Nonetheless, its 
higher expression may play a role in coping with the loss of 
Gnb5; further studies are warranted to elucidate such compen-
satory mechanisms. The expression of Gnb2 is unchanged in the 
cardiac tissue of Gnb5 knockouts; however, it was also linked to 
heart functions in mouse and human66 69 with Gnb2 knockout 
mice having increased HR, and ECG trace revealing shortened 
RR and PQ intervals and ST segment (https://www. mousepheno-
type. org/ data/ genes/ MGI: 95784).85
The transcriptome data provided molecular data supporting an 
increased cardiac function of Gnb5−/− mice. It probably results 
from both a compensatory mechanism, as shown by misexpres-
sion of genes involved in cardiac muscle contractility, and an 
alteration of the expression of genes involved in the regulation 
of the HR. We also documented transcriptional changes in three 
brain regions of knockout mice which correlate with the IDDCA 
neuropsychiatric disease spectrum.
HR regulation by the parasympathetic and sympathetic 
branches of the autonomic nervous system takes place in the 
pacemaker cells of the sinoatrial node. While sympathetic modu-
lation increases pacemaker cell firing rate, the vagal parasym-
pathetic activity decreases the HR. Both activities are mediated 
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by G- protein- coupled signalling on β-adrenergic (sympathetic) 
and cholinergic M2 muscarinic (parasympathetic) receptors, 
respectively. Autonomic innervation is regulated in vivo by RGS 
proteins. In particular, in the heart, the M2 receptor signalling is 
mediated by the Rgs6–Gnb5 complex.17 As Gnb5 and Rgs genes 
are coexpressed and as the physical association of the encoded 
proteins is critical for complex stability, we expected to observe 
reduced Rgs expression levels. In a previous report,17 no Rgs6 
was detected in the atria and in the brain of Gnb5 knockout mice. 
Surprisingly, we detected a trend of increased expression of Rgs 
subunits, in particular Rgs6, contrary to findings in reference7 
where expression of RGS6 was not different between GNB5- 
Ser81Leu and wild- type hiPSCs. These discrepancies may stem 
from the fact that we are investigating different model systems, 
that is, mouse tissues versus human cells, as well as by the use of 
different technologies to detect mRNA abundance; that is, RNA- 
sequencing versus qRT- PCR and that in case of hiPSCs data were 
generated from one clone per genotype.
Altogether, our results unveil that potentially compensatory 
changes occur at a transcriptional level in Gnb5−/− mice through 
higher expression of Gnb3 and Rgs genes in heart tissues. Addi-
tional evidence at protein level did not confirm compensatory 
changes. The previously cited link between GNB5 and the 
R7- RGS RGS6 and RGS11 suggests that they are part of the 
same pathway. Consistent with this hypothesis, the members 
of a Tunisian family presenting with cataract, mental retarda-
tion and microcephaly were carriers of biallelic mutations in 
RGS686 . Another unpublished case harbouring mutation in 
RGS11 presented with overlapping neuropsychiatric pheno-
type (Sarah Montgomery, in litt). No specific cardiac evaluation 
is reported in these individuals, but our data suggest that this 
should be considered. Co- occurrence of neuropsychiatric symp-
toms with visual and cardiac manifestations could represent a 
unique combination associated with Gβ and the R7- RGS related 
proteins. We hypothesise that the disease mechanism responsible 
for HR perturbations is the reduction or the loss of negative 
regulation by Rgs6 on the inhibitory Gβ5 signalling, resulting in 
enhanced parasympathetic activity.
Overall, our work highlights that Gnb5−/− mice not only 
recapitulate IDDCA’s neurological manifestations previously 
outlined elsewhere22 but also mimic its cardiac perturbations, 
especially regarding heart arrhythmias and autonomic nervous 
system control, allowing for future screening of drugs modu-
lating the parasympathetic branch of the autonomic nervous 
system, in view of the development of patients’ therapy.
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